TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05589428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low sodium bread
Description: Bread low in sodium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal bread from bakery
Study: NCT01099280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNPITAN FORT 5 IU
Description: A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propess,SYNPITAN FORT
Description: a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
Study: NCT01957631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (Bupivacaine and Depo Medrol)
Description: The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: 10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
Study: NCT02110082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT03972748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
Study: NCT03560401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knight-Taylor [chairback] brace
Description: Knight-Taylor \[chairback\] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
Study: NCT02620293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eczema Repair Emollient
Description: An Emollient
Study: NCT03218995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Infusion for intravenous use.
Study: NCT05352620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant assisted maxillary overdenture
Description: For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
Study: NCT04126538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone capsule
Description: In the patient group, pirfenidone capsule was taken orally once for 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone capsule
Description: Healthy subjects took pirfenidone capsule 400mg once orally
Study: NCT01238159

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT+MIDLE chemotherapy
Description: Patients are planned to be treated with CCRT plus MIDLE chemotherapy
Study: NCT01981460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue and light treatment
Description: Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
Study: NCT04253418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation (NPS)
Description: Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.
Study: NCT01123811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab IF
Description: Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
Study: NCT02646995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified lipid formulation
Description: Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
Study: NCT03634969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days
Study: NCT02839538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: Injection at perianal region with ropivacaine 0.75%(20ml)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subarachnoidal block
Description: Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
Study: NCT04169269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
Description: anticoagulant, subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 milligram Oral Tablet
Description: anticoagulant, oral
Study: NCT02154607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2-Laser Treatment
Study: NCT02302469

Intervention type: DRUG
Group type: OTHER
Intervention: Revlimid
Description: Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
Study: NCT01343043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(c259)T Cells
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(c259)T Cells
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(c259)T Cells
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(c259)T Cells
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
Study: NCT00583349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, nanoparticle albumin-bound
Description: Intravesically administered, dose escalation, 6 weekly instillations
Study: NCT02306473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Subjects will be challenged with inhaled mannitol according to already approved protocols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Subjects will be challenged with inhaled mannitol according to already approved protocols.
Study: NCT03966573

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiographic imaging
Description: Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating function
Description: Test function and physical capasity

Intervention type: OTHER
Group type: OTHER
Intervention: Forms
Description: Forms for evaluating quality of life, pain, function
Study: NCT06521788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-assisted breast ultrasound
Description: AI-assisted breast ultrasound in community-based breast cancer screening

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine breast ultrasound
Description: Routine breast ultrasound conducted by primary care physicians
Study: NCT03027973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA
Description: Experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for UPA)
Description: Sugar pill manufactured to mimic UPA 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for TEA)
Description: Sugar pill manufactured to mimic TEA 500mg
Study: NCT04141137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® System
Description: The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
Study: NCT03419806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infudopa i.v.
Description: Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infudopa s.c.
Description: A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Study: NCT03673839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based protein blends type 3 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study: NCT02824991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: detection of local twitch response intensities during dry needling
Study: NCT01833221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 1% lidocaine, 2mL for facial nerve block
Description: injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
Study: NCT01566474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
Study: NCT00393770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine
Description: 250-500 mg/kg/die.
Study: NCT04114526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit.
Study: NCT04518319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox aerobic exercise
Description: Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation,tDCS
Description: Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will take only olanzapine pills.
Study: NCT04280393

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy procedure with endocuff
Description: Colonoscopy procedure with the use of ENDOCUFF VISION

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy procedure with endocuff
Description: Colonoscopy procedure with the use of ENDOCUFF VISION
Study: NCT02129530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Social Mobilization program
Study: NCT04259801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0480-0389)
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study: NCT04347031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: 1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mefloquine + azithromycin + / - tocilizumab
Description: 1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin + / - tocilizumab
Description: 1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.
Study: NCT02690584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Study: NCT03371238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floorball
Description: The subjects in this group are set to play floorball three times pr. week for 39 weeks.
Study: NCT02100241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active stretching
Description: The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active stretching
Description: The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
Study: NCT03539731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorine F 18 DASA-23
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DASA-23
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DASA-23
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorine F 18 DASA-23
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT02670200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: treatment technique to help people to overcome psychological distress and mental diseases

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: treatment technique to help people to overcome psychological distress and mental diseases
Study: NCT03149965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transperineal ultrasound
Description: transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transperineal ultrasound
Description: transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
Study: NCT04252508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animated film
Description: An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.